Usman Shah

Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

Heinz‐Josef Lenz, Eric Van Cutsem, María Luisa Limón et al. · Annals of Oncology · 2018 · 92 citations · Full text

Low-dose Ipilimumab, Medicine, Immunology +8

Alterations of LKB1 and KRAS and risk of brain metastasis: Comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma

Ni Zhao, Matthew D. Wilkerson, Usman Shah et al. · Lung Cancer · 2014 · 81 citations · Full text

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.

Heinz‐Josef Lenz, Sara Lonardi, Vittorina Zagonel et al. · Journal of Clinical Oncology · 2020 · 60 citations

Checkmate 142, First-line Therapy, Immunology +17

Photocatalytic degradation of cefixime using CuO-NiO nanocomposite photocatalyst

Zia Ur Rahman, Usman Shah, A. Alam et al. · Inorganic Chemistry Communications · 2022 · 51 citations

Chemical Engineering, Engineering, Green Nanotechnology +5

Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.

Heinz‐Josef Lenz, Sara Lonardi, Vittorina Zagonel et al. · Journal of Clinical Oncology · 2020 · 43 citations

Checkmate 142, Immunology, Pathology +18